Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 2/20 | 0.39 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.39 |
| ▸ | HPGD | P15428 | 1/20 | 0.39 |
| ▸ | ACE | P12821 | 2/20 | 0.39 |
| ▸ | ITGB3 | P05106 | 1/20 | 0.39 |
| ▸ | ITGA2B | P08514 | 1/20 | 0.39 |
| ▸ | TLR2 | O60603 | 1/20 | 0.39 |
| ▸ | TLR1 | Q15399 | 1/20 | 0.39 |
| ▸ | KLK7 | P49862 | 1/20 | 0.38 |
| ▸ | KLK5 | Q9Y337 | 1/20 | 0.38 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.38 |
| ▸ | RECQL | P46063 | 1/20 | 0.38 |
| ▸ | REN | P00797 | 3/20 | 0.38 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.37 |
| ▸ | POLB | P06746 | 1/20 | 0.37 |
| ▸ | MAPT | P10636 | 1/20 | 0.37 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.37 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.37 |
| ▸ | HDAC8 | Q9BY41 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18103825 | 1.00 | MEN1 (0.39) | MEN1KMT2AALDH1A1HPGDACE | |
| SCHEMBL18103810 | 0.91 | ACE (0.42) | KMT2AACEKLK7KLK5REN | |
| SCHEMBL18103807 | 0.91 | ACE (0.42) | KMT2AACEKLK7KLK5REN | |
| SCHEMBL18103803 | 0.89 | ITGB3 (0.39) | MEN1KMT2AITGB3ITGA2BTLR2 | |
| SCHEMBL19181342 | 0.83 | ACE (0.42) | MEN1KMT2AALDH1A1HPGDACE | |
| SCHEMBL19181343 | 0.83 | ACE (0.42) | MEN1KMT2AALDH1A1HPGDACE | |
| SCHEMBL19182039 | 0.83 | ACE (0.42) | MEN1KMT2AALDH1A1HPGDACE | |
| SCHEMBL18103844 | 0.83 | ACE (0.46) | ACEITGB3ITGA2BKLK7KLK5 | |
| SCHEMBL19180861 | 0.83 | ACE (0.46) | ACEITGB3ITGA2BKLK7KLK5 | |
| SCHEMBL18103842 | 0.83 | ACE (0.46) | ACEITGB3ITGA2BKLK7KLK5 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9969772-B2 | Covalent granzyme B inhibitors | VIDA THERAPEUTICS INC. (CA) | 2018-05-15 | — | — | US | disclosed |
| US-20170015707-A1 | COVALENT GRANZYME B INHIBITORS | VIDA THERAPEUTICS INC. (CA) | 2017-01-19 | — | — | US | disclosed |
| US-9458192-B1 | Covalent granzyme B inhibitors | VIDA THERAPEUTICS INC. (CA) | 2016-10-04 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170015707-A1 | COVALENT GRANZYME B INHIBITORS | GZMB, CTSB, DNASE1L3 | MEN1 2527/4885KMT2A 3326/4885ALDH1A1 4621/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.